Fuse Vectors secures USD 5.2 million

Fuse Vectors replaces cell-based production methods of the 1980s with a controlled, biochemical process. The pre-seed round was led by HCVC.

Copenhagen, February 25, 2025 - Danish biotech startup Fuse Vectors has closed a pre-seed financing of USD 5.2 million. The round was led by HCVC, with support from BioInnovation Institute, EIFO and the Innovation Fund. The company will use the funding to further develop its cell-free viral vector platform, making gene and gene therapies faster, cheaper and more accessible.

Cell-free production: faster, more precise, more cost-effective

Traditional gene therapy production methods are based on cell cultures - a technology dating back to the 1980s. These approaches are time-consuming, expensive and often lead to unreliable results. Fuse Vectors is revolutionizing this process with its enzymatic, cell-free platform that assembles viral vectors in a targeted and controlled manner.

Instead of relying on the unpredictable behavior of living cells, we rely on controlled biochemical reactions. In this way, we achieve a precision of over 99 % of filled capsids - in just a few hours instead of weeks

Benjamin Blaha, co-founder of Fuse Vectors

More efficiency and scalability

The modular platform enables rapid prototyping and optimization of gene therapy candidates. Pharmaceutical companies and research institutions can simply provide a gene sequence, while Fuse Vectors takes care of the entire production process.

We see great potential in making gene therapy not only more efficient, but also accessible to more patients.

Henrik Stage, Co-Founder and Executive Chair

Two paths to commercialization

Fuse Vectors is planning two business strategies: on the one hand, partnerships with pharmaceutical companies, biotech companies and academic institutions to optimize their gene therapy candidates with the Fuse Technology and Optimization Engine. On the other hand, the in-house development of a pipeline of therapeutic candidates

The company is already working with seven partners, including leading pharmaceutical companies and research institutions.

Investor comments on the round

Trine Bartholdy, CBO of the BioInnovation Institute, emphasizes: "Fuse Vectors shows how innovative platform technologies can pave the way for more efficient, more accessible gene therapies."

Alexis Houssou, Managing Partner of HCVC, is also convinced: "Fuse Vectors' cell-free solution has the potential to fundamentally change gene therapy and bring transformative treatments to patients faster."